聖諾醫藥-B(02257.HK)公佈2022年度業績 研發開支大幅增加66%
格隆匯3月28日丨聖諾醫藥-B(02257.HK)公佈2022財政年度業績,研發開支增加至6760萬美元,較截至2021年12月31日止年度的4070萬美元增加2690萬美元或66%。該增加主要由於:(i)化學、製造及控制開支以及所消耗的物料;及(ii)臨牀試驗開支及臨牀前試驗開支。有關增加與集團持續研發工作一致,以支持集團穩步推進及擴大候選藥物管線。
集團的年內虧損由截至2021年12月31日止年度的2.16億美元減少至截至2022年12月31日止年度的9740萬美元。虧損減少主要歸因於按公平值計入損益的金融負債的公平值變動虧損及上市開支減少,部分由研發開支及行政開支增加所抵銷。
於2022財政年度及2023年第一季度,集團繼續推進集團的藥物管線及業務運營。憑藉集團專有的雙重遞送技術平台—PNP及GalAheadTM,集團已建立起豐富的臨牀管線,從最初專注於腫瘤及纖維化療法,擴展至抗凝療法、心血管代謝疾病、補體介導相關的疾病及病毒感染以及醫學美容。隨着STP705進入了治療NMSC的後期臨牀開發階段,其鞏固了集團在全球癌症治療的RNA藥物中的領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.